Key result
Ivabradine safely cuts heart rate ~19% in a neonate with refractory ectopic atrial tachycardia.
Why the study?
Neonatal ectopic atrial tachycardia is a rare arrhythmia that may be resistant to conventional therapy.
Does ivabradine reduce heart rate in a neonate with refractory ectopic atrial tachycardia?
Case Report (n=1)
No
Does ivabradine reduce heart rate in a neonate with refractory ectopic atrial tachycardia?
Ivabradine provided rapid and sustained heart rate control without haemodynamic compromise in a neonate with refractory ectopic atrial tachycardia.
Answers are grounded in this paper and cite their sources.
May control heart rate in refractory neonatal ectopic atrial tachycardia without hemodynamic compromise; hypothesis-generating and requires prospective validation.
Neonatal ectopic atrial tachycardia is a rare arrhythmia that may be resistant to conventional therapy. We report a neonate with persistent foetal tachycardia refractory to flecainide and digoxin. Ivabradine resulted in rapid and sustained heart rate reduction without haemodynamic compromise. This case supports ivabradine as a therapeutic option in neonatal automatic tachycardias when standard treatments fail.
No takes yet. Share an insight, caveat, or question.
Adell et al. (2026) conducted a case report in Refractory neonatal ectopic atrial tachycardia (n=1). Ivabradine vs. Flecainide and digoxin (prior therapy) was evaluated on Mean heart rate (beats per minute). Ivabradine successfully reduced the mean heart rate from 171 to 139 beats per minute in a neonate with refractory ectopic atrial tachycardia, without causing haemodynamic compromise.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: